ALDX News and Press, Aldeyra Therapeutics Inc. From 11/01/23

2023-11-01 08:17:45 ET More on AbbVie, Aldeyra Therapeutics, etc. AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it has entered into an exclusive option agreement with AbbVie Inc. (AbbVie). Under the terms...

2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...

2023-10-19 14:25:47 ET More on Aldeyra Therapeutics Eyeing Returns: Aldeyra's Shift From Lab To Market Aldeyra says FDA may not approve dry eye drug, stock plunges 69% (update) Seeking Alpha’s Quant Rating on Aldeyra Therapeutics Historical earnings da...

2023-10-18 08:27:42 ET Nuzee ( NUZE ) -33% on proposed public offering of shares . SciSparc ( SPRC ) -16% . Notable Labs (NTBL) -10% . Genmab ( GMAB ) -9% . Maison Solutions ( MSS ) -8% . Aldeyra Therapeutics ( ALDX ...

2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...

2023-10-16 10:54:01 ET More on Aldeyra Therapeutics Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash Eyeing Returns: Aldeyra's Shift From Lab To Market Seeking Alpha’s Quant Rating on Aldeyra Therapeutics Historical earnings data for Alde...

2023-10-16 10:00:00 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...

2023-09-22 19:44:16 ET Summary Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their lead asset, reproxalap, is under NDA review for dry eye disease and has shown positive results in ph...

2023-09-18 18:10:11 ET Summary Aldeyra Therapeutics' Q2 2023 report reveals a 52% cut in R&D spending, signaling a shift towards market readiness and commercial activities. The company maintains strong financial health with $151.7M cash reserves and a 40-month cash runway, red...